1. A comparison of decision and timing of safety related labeling changes for new drugs approved both in Japan and the United States. Issue 5 (18th February 2021) Authors: Hoshino, Yuko; Narukawa, Mamoru Journal: Pharmacoepidemiology and drug safety Issue: Volume 30:Issue 5(2021) Page Start: 561 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers. Issue 1 (22nd July 2018) Authors: Yamashita, Kenji; Kaneko, Masayuki; Narukawa, Mamoru Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 1(2019) Page Start: 153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers' Information Sources. (17th March 2022) Authors: Takada, Shunsuke; Narukawa, Mamoru Journal: International journal of technology assessment in health care Issue: Volume 38:Number 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Analysis of factors related to the occurrence of important drug‐specific postmarketing safety‐related regulatory actions: A cohort study focused on first‐in‐class drugs. Issue 12 (10th August 2018) Authors: Ikeda, Junji; Kaneko, Masayuki; Narukawa, Mamoru Journal: Pharmacoepidemiology and drug safety Issue: Volume 27:Issue 12(2018) Page Start: 1393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. (14th November 2022) Authors: Inoue, Takashi; Narukawa, Mamoru Journal: Cancer control Issue: Volume 29(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. (14th November 2022) Authors: Inoue, Takashi; Narukawa, Mamoru Journal: Cancer control Issue: Volume 29(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Issue 3 (8th April 2021) Authors: Yamaguchi, Shingo; Kaneko, Masayuki; Narukawa, Mamoru Journal: Clinical and translational science Issue: Volume 14:Issue 3(2021) Page Start: 1113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. Issue 7 (July 2018) Authors: Kaneko, Masayuki; Narukawa, Mamoru Journal: Annals of pharmacotherapy Issue: Volume 52:Issue 7(2018) Page Start: 632 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio. (July 2017) Authors: Kaneko, Masayuki; Narukawa, Mamoru Journal: Annals of pharmacotherapy Issue: Volume 51:Number 7(2017:Jul.) Page Start: 570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Non–Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease. (27th April 2022) Authors: Yamaguchi, Shingo; Narukawa, Mamoru Journal: Journal of clinical pharmacology Issue: Volume 62:Number 10(2022) Page Start: 1247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗